Long-term double-blind extension study of itepekimab in COPD

Double-blind trial of itepekimab in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Sanofi. Primary endpoint: Incidence of treatment-emergent adverse events, adverse events of special interest, serious adverse events, and adverse events leading to permanent treatment discontinuation. Started Apr 2024; status: active, not recruiting.